Provided by Tiger Fintech (Singapore) Pte. Ltd.

MiNK Therapeutics, Inc.

64.17
+56.44730.14%
Post-market: 51.20-12.9700-20.21%19:59 EDT
Volume:47.86M
Turnover:2.47B
Market Cap:255.76M
PE:-25.69
High:76.00
Open:21.07
Low:20.20
Close:7.73
Loading ...

24H|BIT Mining Rose 12%; Canaan Up 8%; SharpLink Up 5%; MiNK Therapeutics Tumbled 20%; Wolfspeed Slumped 5%

Tiger Newspress
·
60 mins ago

Why Is MiNK Therapeutics Stock (INKT) Up 190% Today?

TIPRANKS
·
12 Jul

MiNK Therapeutics downgraded to Market Perform from Outperform at William Blair

TIPRANKS
·
12 Jul

MiNK Therapeutics (INKT) was downgraded to a Hold Rating at William Blair

TIPRANKS
·
12 Jul

MiNK data published showing complete remission, says H.C. Wainwright

TIPRANKS
·
11 Jul

Promising Clinical Results and Positive Outlook for MiNK Therapeutics’ agenT-797 Drive Buy Rating

TIPRANKS
·
11 Jul

Mink Therapeutics Inc trading halted, volatility trading pause

TIPRANKS
·
11 Jul

MiNK Therapeutics announces publication of complete remission using agenT-797

TIPRANKS
·
11 Jul

BRIEF-Mink Therapeutics Announces Publication Of Complete Remission

Reuters
·
11 Jul

Mink Therapeutics Announces Promising Results of Allogeneic iNKT Cell Therapy, Achieving Complete Remission in Metastatic Testicular Cancer

Reuters
·
11 Jul

Mink Therapeutics Announces Publication of Complete Remission Following Allogeneic Inkt Cell Therapy in Metastatic Testicular Cancer

THOMSON REUTERS
·
11 Jul

MiNK Therapeutics Holds Annual Stockholders Meeting

TIPRANKS
·
19 Jun

Mink Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
19 Jun

Press Release: MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

Dow Jones
·
11 Jun

MiNK Therapeutics Secures NIAID Grant to Advance Allo-iNKT Cell Therapy for GvHD Prevention in Collaboration with University of Wisconsin

Reuters
·
02 Jun

Mink Therapeutics Awarded Prestigious Niaid Grant to Advance Allo-Inkt Cell Therapy for Prevention of Gvhd in Stem Cell Transplant Patients

THOMSON REUTERS
·
02 Jun

MiNK Therapeutics: Promising Clinical Trials and Strategic Plans Justify Buy Rating

TIPRANKS
·
15 May

Mink Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
15 May

MiNK Therapeutics Q1 EPS $(0.70) Beats $(0.71) Estimate

Benzinga
·
15 May

MiNK Therapeutics Reports Q1 2025 Results: Net Loss Decreases to $2.8 Million, EPS Improves to $(0.70)

Reuters
·
15 May